+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Arcapta

  • ID: 4775196
  • Report
  • July 2018
  • Region: Global
  • 16 pages
  • Datamonitor Healthcare
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
Drug Overview
Novartis has developed Arcapta (indacaterol; marketed as Onbrez outside the US) for use in its Breezhaler/Neohaler dry-powder inhaler for the treatment of chronic obstructive pulmonary disease (COPD). As the first once-daily long-acting beta 2 agonist (LABA) to launch in the COPD market, Arcapta has seen high use as an add-on therapy to the gold-standard long-acting muscarinic antagonist (LAMA), Spiriva (tiotropium; Boehringer Ingelheim). Due to the increasing availability of fixed-dose LABA/LAMA combination therapies, including Sunovion and Novartis’s Utibron Neohaler ([indacaterol + glycopyrrolate]), and a number of triple-combination therapies having been launched, the author does not forecast Arcapta to continue being used as an add-on therapy to Spiriva or other LAMA monotherapies. Instead, Arcapta is expected to be predominantly used as a monotherapy in mild and moderate patients.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Arcapta Neohaler: Chronic obstructive pulmonary disease (COPD)

LIST OF FIGURES
Figure 1: Arcapta for COPD – SWOT analysis
Figure 2: The authors drug assessment summary of Arcapta for COPD
Figure 3: The authors drug assessment summary of Arcapta for COPD
Figure 4: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Arcapta drug profile
Table 2: Arcapta Phase III data in COPD
Table 3: Arcapta Neohaler sales for COPD across Japan and the five major EU markets, by country ($m), 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll